X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse ALEMBIC PHARMA with ACTAVIS INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs ACTAVIS (US) - Comparison Results

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 ALEMBIC PHARMA   ACTAVIS
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-19
ACTAVIS
Dec-18
ALEMBIC PHARMA/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs66413,317-   
Low Rs4128,933-   
Sales per share (Unadj.) Rs208.73,266.6-  
Earnings per share (Unadj.) Rs31.0-1,052.2-  
Cash flow per share (Unadj.) Rs37.1344.2-  
Dividends per share (Unadj.) Rs5.500-  
Dividend yield (eoy) %1.00-  
Book value per share (Unadj.) Rs144.213,473.1-  
Shares outstanding (eoy) m188.52332.60-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.63.4 75.7%   
Avg P/E ratio x17.4-10.6 -164.2%  
P/CF ratio (eoy) x14.532.3 44.9%  
Price / Book Value ratio x3.70.8 452.0%  
Dividend payout %17.70-   
Avg Mkt Cap Rs m101,4613,700,093 2.7%   
No. of employees `000NA16.9 0.0%   
Total wages/salary Rs m7,4670-   
Avg. sales/employee Rs ThNM64,287.7-  
Avg. wages/employee Rs ThNM0-  
Avg. net profit/employee Rs ThNM-20,707.1-  
INCOME DATA
Net Sales Rs m39,3471,086,461 3.6%  
Other income Rs m9420,777 0.5%   
Total revenues Rs m39,4411,107,238 3.6%   
Gross profit Rs m8,73628,471 30.7%  
Depreciation Rs m1,152464,439 0.2%   
Interest Rs m18462,695 0.3%   
Profit before tax Rs m7,493-477,886 -1.6%   
Minority Interest Rs m110-   
Prior Period Items Rs m-930-   
Extraordinary Inc (Exp) Rs m0121,880 0.0%   
Tax Rs m1,568-6,056 -25.9%   
Profit after tax Rs m5,844-349,950 -1.7%  
Gross profit margin %22.22.6 847.2%  
Effective tax rate %20.91.3 1,650.7%   
Net profit margin %14.9-32.2 -46.1%  
BALANCE SHEET DATA
Current assets Rs m19,577445,610 4.4%   
Current liabilities Rs m14,896394,201 3.8%   
Net working cap to sales %11.94.7 251.4%  
Current ratio x1.31.1 116.3%  
Inventory Days Days9020 458.2%  
Debtors Days Days4566 68.4%  
Net fixed assets Rs m27,097122,981 22.0%   
Share capital Rs m3770-   
"Free" reserves Rs m26,8110-   
Net worth Rs m27,1884,481,145 0.6%   
Long term debt Rs m4,9931,577,974 0.3%   
Total assets Rs m47,7787,005,050 0.7%  
Interest coverage x41.7-6.6 -629.7%   
Debt to equity ratio x0.20.4 52.2%  
Sales to assets ratio x0.80.2 531.0%   
Return on assets %12.6-4.1 -307.7%  
Return on equity %21.5-7.8 -275.2%  
Return on capital %23.6-4.8 -487.6%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m13,3880-   
CASH FLOW
From Operations Rs m8,120388,152 2.1%  
From Investments Rs m-7,556213,239 -3.5%  
From Financial Activity Rs m590-666,184 -0.1%  
Net Cashflow Rs m1,153-64,471 -1.8%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 68.82 Rs / USD

Compare ALEMBIC PHARMA With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare ALEMBIC PHARMA With: FULFORD INDIA  CADILA HEALTHCARE  WYETH LTD  DIVIS LABORATORIES  JUBILANT LIFE SCIENCES  



Today's Market

Yes Bank's Road Ahead(Podcast)

The stock markets witnessed selling pressure in the week gone by. Market participants remained cautious tracking tepid quarterly earnings amid weak cues.

Related Views On News

ALEMBIC PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 13, 2019 | Updated on Jun 13, 2019

Here's an analysis of the annual report of ALEMBIC PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

ALEMBIC PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 28.9% (Quarterly Result Update)

May 9, 2019 | Updated on May 9, 2019

For the quarter ended March 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.6% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 21, 2018 | Updated on Dec 21, 2018

Here's an analysis of the annual report of ALEMBIC PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

ALEMBIC PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 61.0% (Quarterly Result Update)

Oct 23, 2018 | Updated on Oct 23, 2018

For the quarter ended September 2018, ALEMBIC PHARMA has posted a net profit of Rs 2 bn (up 61.0% YoY). Sales on the other hand came in at Rs 11 bn (up 42.8% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound (Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On... (The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors (The 5 Minute Wrapup)

Jul 8, 2019

A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...

Here's What to Do with Falling Small Cap Stocks (Profit Hunter)

Jul 10, 2019

There are some great buying opportunities in the market right now - and the small cap space is your best bet.

Budget an Icing on the Cake for This Smart Money Backed Affordable Housing Stock (The 5 Minute Wrapup)

Jul 10, 2019

Affordable housing is one of the most straightforward growth stories in India. This will help the real estate sector to come out of the slump.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Jul 19, 2019 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA 5-YR ANALYSIS

COMPARE ALEMBIC PHARMA WITH

MARKET STATS